Alcohol abstinence reduced #cirrhosis decompensation risk even in people with high portal pressure 1️⃣i ❤️good news 2️⃣study would have benefitted from peth 3️⃣👏👏first author Dr Hofer #livertwitter pubmed.ncbi.nlm.nih.gov/36481475/ CGH

New content online: Liver diseases and hepatocellular carcinoma in the Asia-Pacific region: burden, trends, challenges and future directions dlvr.it/TC0Zrj

❓One NIT to rule them all, one NIT to find them (LiverRisk)❓ ▶️Developed in prim./sec. care for estimating LSM, LiverRisk doesn't outperform FIB-4 for cACLD diagnosis in tert. care 🤯FIB-4 (& LSM) better for pred. decomp. 👉Avoid surrogates of surrogates - 🎯direct endp. 🔗👇

📑 Noninvasive predictors of clinically significant portal hypertension in #NASH cirrhosis❗️ 1️⃣ANTICIPATE (TE+Plt) & ANTICIPATE-NASH (+BMI) predict CSPH 2️⃣New model, ⭐️ FIB4+ (FIB4+Albumin), also predicts CSPH and does not require elastography❕ journals.lww.com/hepcomm/fullte…

1⃣Porto-sinusoidal vascular liver disorder (PSVD) is a rare entity that causes portal hypertension. 2⃣PSVD must be suspected in patients with portal hypertension and lower liver stiffness and HVPG values than those expected in cirrhosis. journal-of-hepatology.eu/article/S0168-…

The impact of TIPS on waitlist outcomes in Budd-Chiari. journals.lww.com/lt/abstract/99…

Screening for cirrhosis ready to go⁉️ #LiverTwitter ✅Management more effective in compensated vs decomp ✅MASLD & weight-loss drugs better in pre-cirrhosis ✅Screening improves case finding ✅Guideline recommended 🚫Ample knowledge gaps - read here: journals.lww.com/hepcomm/fullte…

pubmed.ncbi.nlm.nih.gov/39181168/ 💥 Recompensation in 24.7% 24.7% of 1152 HCV related cirrhosis patients following SVR-12, portal hypertension progressed in 13.7% and 2.9% had a new development of HCC over 48 months follow-up. Data from Punjab, India 🇮🇳 Radha K Dhiman

🆕Article in press❕ Identifying the optimal measurement timing and hemodynamic targets of portal pressure gradient after TIPS in patients with cirrhosis and variceal bleeding: a prospective cohort study Read it here👉journal-of-hepatology.eu/article/S0168-… #LiverTwitter

Porto-sinusoidal vascular liver disorder with portal hypertension: Natural History and Long-Term Outcome. - Journal of Hepatology journal-of-hepatology.eu/article/S0168-… Proud of this collaborative effort. Thanks to all VALDIG, ERN centers Hospital Clínic IDIBAPS ERN RARE LIVER CIBERehd

How to combine FIB-4 and Elastography to screen for liver fibrosis ? Which algorithms are proposed by the main liver/GI societies ? I find this summarizing figure very useful. t.ly/V6cvF

Check out our latest paper : Risk of major bleeding in patients with and without cirrhosis undergoing percutaneous procedures. : Liver Transplantation journals.lww.com/lt/abstract/99…. The risk is low!

How much 🍻Alcohol is in #MASLD? important to know sind it does make difference! 📕t.ly/RdHD- but #PortalHypertension remains a key driver of #liver #Events 📕t.ly/GUx2Q Reply 📨 t.ly/BQetE by @wilcokwanten Benedikt Hofer Sven Francque

Check-out our last article! 🔽 β-blockers lower first decompensation in patients with cirrhosis and enduring portal hypertension after etiological treatment. Madalina Gabriela Taru Horia Stefanescu bogdan procopet The Baveno Cooperation: an EASL Consortium cghjournal.org/article/S1542-…

🆕Article in press❕ Porto-sinusoidal vascular liver disorder with portal hypertension: Natural History and Long-Term Outcome Read it here👉journal-of-hepatology.eu/article/S0168-… #LiverTwitter

While self-reported #Alcohol consumption performs ok - at least wtihin clinical trials #PEth seems to be the most reliable alcohol #biomarker - in regard to prediction of #liver-related events #decompensation The Baveno Cooperation: an EASL Consortium EASLnews Congrats Mads Israelsen in JHEP Reports

>50% #cirrhosis pts w cognitive issues🚫have #hepaticencephalopathy & #microbiome profile differs but is this ready to use? ✅machine learning paper pubmed.ncbi.nlm.nih.gov/39189586 >300 pts➡️💩>80% HE specificity, ⬆️stakeholder acceptance, 3 ctr validation➡️changed HE diagnosis in >40%

1/ 🧵Porto-sinusoidal vascular disorder (#PSVD) is a rare condition. Despite its known hallmarks, much remains unclear, including its pathobiology and the potential for non-invasive testing. Our paper explores PSVD from a metabolomics angle: jhep-reports.eu/article/S2589-…

/4 Together with colleagues from the University of Barcelona Clinical Hospital, we showed the role of taurocholic acid or taurocholic/L-aspartic acid ratio in distinguishing PSVD from healthy and cirrhosis profiles accordingly (AUROC = 0.9 / 0.72) in validation. Img: Fig. 5E

Are all #infections in #cirrhosis equal worldwide? No! Striking regional variations due to culture resources & antibiotic overuse ✅The Lancet Gastroenterology & Hepatology from CLEAREDConsortium w >4000 pts⤵️ authors.elsevier.com/a/1jj7R8nByrCi… Join▶️clearedconsortium.org 💯comment Salvatore Piano Dr Nipun Verma